Skip to Main content Skip to Navigation
Journal articles

Pembrolizumab for the treatment of colorectal cancer

Abstract : Introduction: Colorectal cancer (CRC) is one of the most frequent and lethal cancers in the world, and therapies are still insufficient. Immune checkpoint inhibitors (ICI) in metastatic CRC (mCRC) have not revolutionized treatment to the extent that they have in melanoma or renal carcinoma. Their use is limited to a molecular niche of mCRC with microsatellite instability (MSI). This review summarizes clinical data published with pembrolizumab in mCRC and also tries to identify potential new strategies. Areas covered: This paper focuses on pembrolizumab in mCRC. We screened all trials on PubMed and ClinicalTrials.gov and describe the most significant ones in our opinion. Expert opinion: Pembrolizumab seems to be effective in tumors with MSI-high status. It defines a new horizon for therapeutic strategy called 'agnostic' medicine. For microsatellite stable (MSS) colorectal cancers, the future challenge will be to successfully redraw the immune microenvironment to make it immunogenic with new therapeutic combinations, including ICI
Document type :
Journal articles
Complete list of metadatas

Cited literature [70 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02547539
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, April 20, 2020 - 9:51:13 AM
Last modification on : Friday, June 19, 2020 - 1:40:06 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Dahna Coupez, Pauline Hulo, Yann Touchefeu, Céline Bossard, Jaafar Bennouna. Pembrolizumab for the treatment of colorectal cancer. Expert Opinion on Biological Therapy, Informa Healthcare, 2020, 20 (3), pp.219-226. ⟨10.1080/14712598.2020.1718095⟩. ⟨inserm-02547539⟩

Share

Metrics

Record views

90